COVID-19 Booster Reduces Delta Variant Mortality by 90%

Article

An Israeli study found that a third “booster” shot of the Pfizer-BioNTech vaccine reduced the risk of COVID-19 death by 90%.

An Israeli study found that a third “booster” shot of the Pfizer-BioNTech vaccine reduced the risk of COVID-19 death by 90%.

The emerging Omicron variant has recently dominated news cycles and public concern, but 95% of COVID-19 infections in the US are still caused by the Delta variant.

Luckily, an Israeli study published this week found that 3 doses of the Pfizer-BioNTech vaccine (2 initial doses and 1 “booster” dose at least 5 months later) reduce the risk of dying from the Delta variant by 90%.

The study consisted of 843000 Israelis who received an initial 2-dose series of Pfizer-BioNTech and were eligible for a booster vaccination. Of this cohort, approximately 758000 opted to receive a Pfizer-BioNTech booster.

The study ran from August-September 2021, during which Delta was the predominant COVID-19 strain in Israel. During this study period, 65 participants who received a third booster dose died, compared to 137 deaths in the non-booster group.

A second Israeli study of 4.7 million participants fully vaccinated with Pfizer-BioNTech found those who received a booster had a ten-fold reduction in COVID-19 infection. Additionally, resistance to Delta increased the longer the booster vaccine was in a person’s system.

Pfizer-BioNTech boosters were recently authorized for all US adults and adolescents 16-17 years of age.

On Wednesday, Pfizer-BioNTech released data showing 3 doses of their COVID-19 vaccine neutralized the Omicron variant. Omicron’s mutations are still 80% susceptible to Pfizer-BioNTech’s vaccine, and while 2 doses likely still protect against severe disease, a booster dose significantly increases resistance.

Notably, however, a third dose boosts antibody levels back to where they were before the emergence of Omicron. Pfizer-BioNTech is continuing to test the efficacy of 2 and 3 doses of its vaccine against the current and any subsequent variants.

Newsletter

Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.

Recent Videos
© 2025 MJH Life Sciences

All rights reserved.